What is Avenue Therapeutics Financial Strength?
Avenue Therapeutics has the Financial Strength Rank of 9. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Avenue Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Avenue Therapeutics has no long-term debt (1).
As of today, Avenue Therapeutics's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Avenue Therapeutics's Financial Strength
For the Biotechnology subindustry, Avenue Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's Financial Strength falls into.
Avenue Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Avenue Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-3.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Avenue Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| Avenue Therapeutics had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Avenue Therapeutics Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Avenue Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Avenue Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (Avenue Therapeutics) Business Description
Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
Executives
| Rosenwald Lindsay A Md |
director |
375 PARK AVE, NEW YORK NY 10152 |
| Fortress Biotech, Inc. |
10 percent owner |
1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154 |
| Invagen Pharmaceuticals, Inc. |
10 percent owner |
SITE B, 7 OSER AVE., HAUPPAUGE NY 11788 |
| Alexandra Maclean |
officer: Chief Executive Officer |
C/O AVENUE THERAPEUTICS, INC., 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NC 10014 |
| Faith L. Charles |
director |
ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019 |
| David Jin |
officer: Int. PEO, Int. PFO, and COO |
C/O AVENUE THERAPEUTICS, INC., 1140 AVENUE OF THE AMERICAS, FLOOR 9, NEW YORK NY 10036 |
| Joseph Walter Vazzano |
officer: Chief Financial Officer |
1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
| Neil Herskowitz |
director |
2109 BROADWAY, SUITE 206, NEW YORK NY 10023 |
| Curtis Gale Oltmans |
director |
C/O ARRAY BIOPHARMA INC., 3200 WALNUT ST., BOULDER CO 80301 |
| Jay D Kranzler |
director |
4350 EXECUTIVE DRIVE, SUITE 325, SAN DIEGO CA 92121 |
| Lucy Lu |
director, officer: President, CEO |
THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137 |
| Elizabeth Garrett Ingram |
director |
30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362 |
| Thomas Gregory Moore |
director |
C/O AKORN, INC., 1925 WEST FIELD COURT, SUITE 300, LAKE FOREST IL 60045 |
| Nishant Saxena |
director |
CIPLA HOUSE, PENINSULA BUSINESS PARK, LOWER PAREL, MUMBAI K7 400013 |
| Jaideep Ashok Gogtay |
director |
CIPLA LTD., MUMBA CENTRAL, BESIDE CITY CENTER, MUMBAI K7 400008 |
Avenue Therapeutics (Avenue Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ATXI has been successfully added to your